Your session is about to expire
← Back to Search
Sarilumab + Immunotherapy for Melanoma
Study Summary
This trial will test the safety and effectiveness of a new drug combination for advanced melanoma. The new drug, sarilumab, will be given with ipilimumab, nivolumab, and relatlimab to see if it is safe and if it works better than other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am willing and able to follow the study's schedule and requirements.You have a known autoimmune disease that is currently active or suspected, unless you have specific conditions that are allowed.I have signed the consent form for this study.I haven't taken high-dose steroids or other immune-weakening drugs in the last 14 days.I haven't had any treatment for cancer that has spread, with some exceptions.The disease must be able to be measured using a specific set of guidelines called RECIST 1.1.My melanoma is at Stage IIIb/c/d or IV and cannot be removed with surgery.I have melanoma, but it's not in my eye.My cancer's current state is confirmed by recent exams and scans.I do not have untreated brain metastases, carcinomatosis meningitis, or current ocular/uveal melanoma.I had cancer other than melanoma, was treated successfully over 2 years ago, and don't need more treatment.
- Group 1: Study Group
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What end goals are being examined in this scientific endeavor?
"The primary endpoint of this medical trial, evaluated over a 24-day (+/-7 days) time frame, is the number of Treatment-Related Grade 3 to 5 Immune Adverse Events (irAEs) according to NCI CTCAE v5.0 standards. Other outcomes include the Immune Response Rate (irRR), Disease Control Rate (DCR), and Best Overall Responses (iBOR). These parameters are defined as irRC criteria for immune responses, RECIST 1.1 guidelines regarding tumour size reductions or stability, and iBOR which evaluates patient's initial response until progression or death is documented.."
What dangers are associated with taking the medication Nivolumab/Relatlimab?
"Despite the lack of evidence for efficacy, our team at Power assigned a rating of 2 indicating relative safety due to its Phase 2 status."
What demographic is eligible to partake in this research?
"This clinical trial is enrolling 69 individuals aged 18 to 100 with melanoma who meet the following criteria: they must have signed an approved Informed Consent Form, be willing and able to comply with scheduled visits, tests and treatments; possess histologically-confirmed melanoma that is deemed inoperable according to AJCC Cancer Staging Manual (8th Edition), not having received prior anticancer treatment for metastatic disease (exceptions made); their status documented by physical examination and imaging studies within 4 weeks of first dose of study drug; disease measurable by RECIST 1.1; baseline radiographic images available before treatment initiation."
Does this research study encompass individuals beyond the age of 65?
"This clinical trial only admits participants aged 18 to 100. For patients younger than 18, there are 52 separate trials while seniors over 65 have access to 742 different medical studies."
Are fresh participants being accepted for this medical experiment?
"This clinical trial is no longer recruiting, with its initial posting on December 1st 2022 and subsequent update taking place on October 31st. Despite this, 754 other trials are currently searching for volunteers to aid in their research."
Share this study with friends
Copy Link
Messenger